Additionally, we believe that these results may be useful for the synthesis of new hCA I and II isoenzymes, AChE and BChE inhibitors, and in the development of drugs for the treatment of some common and global diseases including edema, epilepsy, glaucoma, mountain sickness, and AD. Here, CYP24A1 is linked to glaucoma.